文献速递淋巴瘤

血清游离脂肪酸促进外周T细胞淋巴瘤进展并预测golidocitinib敏感性

Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma.
PubMed 文献 · Blood Adv · 2026-01-01

该研究分析557例初诊PTCL患者血清代谢谱,发现高游离脂肪酸(FFA)是各亚型不良预后标志物,并与JAK-STAT激活及抑制性微环境相关。选择性JAK1抑制剂golidocitinib在棕榈酸诱导的高FFA条件下及高脂饮食小鼠模型中显示抗肿瘤疗效,且高血清FFA的复发/难治PTCL患者对golidocitinib反应更优。

要点

  • 高血清FFA是PTCL各亚型的不良预后标志物。
  • FFA与JAK-STAT激活及MDSC/M2巨噬细胞浸润相关。
  • 高FFA的复发/难治PTCL患者对golidocitinib反应更优。

核心结论

  • 高血清FFA与PTCL肿瘤进展相关,并提示golidocitinib敏感性。

研究设计与样本

  • 分析557例初诊PTCL患者血清代谢谱,包括278例NKTCL、117例nTFHL、92例PTCL-NOS、36例ALK阳性ALCL和34例ALK阴性ALCL。

主要发现

  • 高FFA被确定为跨PTCL亚型的不良预后生物标志物。
  • 血清FFA与JAK-STAT信号激活相关,NKTCL中单核细胞MDSC浸润增加,nTFHL和PTCL-NOS中M2巨噬细胞浸润增加。
  • golidocitinib在棕榈酸诱导的高FFA共培养体系及高脂饮食同系和异种移植小鼠淋巴瘤模型中显示显著抗肿瘤疗效,通过JAK-STAT-IL-6/IL-10轴抑制MDSC和M2巨噬细胞。
  • 高血清FFA的复发或难治PTCL患者对golidocitinib治疗反应优于低血清FFA患者。

临床怎么用

  • 血清FFA可能作为PTCL预后评估和golidocitinib疗效预测的生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral T-cell lymphoma (PTCL) is an aggressive and heterogeneous lymphoma subtype with high chemoresistance and poor prognosis. Common peripheral blood disease biomarkers with therapeutic potential are lacking. In this study, we analyzed the serum metabolic profiles of 557 patients with newly diagnosed PTCL, including 278 extranodal natural killer/T-cell lymphoma (NKTCL), 117 patients with nodal T-follicular helper cell lymphoma (nTFHL), 92 with PTCL, not otherwise specified (PTCL-NOS), 36 with anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma (ALCL), and 34 with ALK-negative ALCL. We identified high free fatty acid (FFA) as an adverse prognostic biomarker across PTCL subtypes. Integrative analysis of transcriptomic and single-cell RNA-sequencing data sets further revealed that serum FFA linked to JAK-STAT signaling activation and a suppressive tumor microenvironment, characterized by increased infiltration of monocytic myeloid-derived suppressor cells (MDSCs) in NKTCL and M2 macrophages in nTFHL and PTCL-NOS, respectively. The selective JAK1 inhibitor golidocitinib showed pronounced antitumor efficacy in coculture systems under palmitic acid-induced high-FFA conditions and in syngeneic and xenograft murine lymphoma models fed with high-fat diet through the JAK-STAT- interleukin-6 (IL-6)/IL-10 axis-mediated inhibition of MDSCs in NKTCL and M2 macrophages in nTFHL and PTCL-NOS, respectively. In alignment with our experimental findings, relapsed or refractory patients with PTCL, who had high serum FFA levels, exhibited superior responses to golidocitinib treatment than those with low serum FFA levels. Collectively, high serum FFA is related to tumor progression and indicates golidocitinib sensitivity, providing novel insights into reprogramming lipid metabolism to dually target the tumor and microenvironment in PTCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Qin Y, Xia PH, Huang YH, et al. Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma. Blood Adv. 2026. PMID: 41564436. doi:10.1182/bloodadvances.2025017682

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。